Published: 19 March 2022
Author(s): Gema M. Lledó, Marc Xipell, Adriana García-Herrera, Laura Bueno, Ricard Cervera, Maria Galindo, Jose A. Gómez-Puerta, Enrique Morales, Manuel Praga, Jorge E. Rojas, Guillermo Ruiz-Irastorza, Olga Sánchez Pernaute, David Jayne, Gerard Espinosa, Luis F. Quintana, Multidisciplinary Group for the Study of Lupus Nephritis
Issue: May 2022
Section: Clinical Insights

Systemic lupus erythematosus (SLE) is the classical systemic autoimmune disease with heterogeneous manifestations and unpredictable behaviour in which almost 70% may have a relapsing-remitting course, while 30% are divided equally between prolonged remission and persistently active disease [1]. According to the mosaic of autoimmunity [2], immune responses (innate and adaptative), as well as interaction of genes with environmental factors (ultraviolet radiation, smoking and drugs, such as, procainamide, hydralazine and anti-tumour necrosis factor agents) lead to numerous immunologic abnormalities that culminate in persistent immune responses against autologous nucleic acids.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.